1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Nanjing Sinolife United Co., Ltd. Class H

Nanjing Sinolife United Co., Ltd. Class H

HHKEX:3332
0.17
HKD
-0.01
(-7.78%)
361.02MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.33
0.31
0.47
0.53
0.5
0.48
0.34
0.31
0.27
0.29
0.6
0.79
0.82
- -
Basic EPS, GAAP
0.12
0.13
0.16
0.1
- -
-0.12
-0.21
-0.05
-0.03
-0.02
0.06
0.04
0.03
- -
Free Cash Flow per Basic Share
0.13
0.09
0.1
0.06
-0.16
-0.02
-0.09
- -
-0.01
- -
0.05
-0.01
0.07
- -
Dividend per Share
0.1
- -
0.12
0.15
0.11
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.3
0.75
0.79
0.87
0.76
0.64
0.43
0.38
0.35
0.34
0.4
0.42
0.44
0.44
Tangible Book Value per Share
0.3
0.75
0.71
0.61
0.51
0.47
0.34
0.32
0.31
0.3
0.36
0.38
0.41
0.41
Basic Weighted Avg Shares
589
826
838
876
946
946
946
946
946
946
946
946
946
946
Sales/Revenue/Turnover
195
252
397
466
472
453
323
297
252
275
564
748
773
- -
Operating Margin (%)
47.75
51.55
43.43
24.5
7.47
-11.76
-34.24
-10.09
-12.5
-4.4
10.46
5.6
3.27
- -
Depreciation Expense
3
3
7
12
11
13
23
22
19
15
14
14
13
- -
Net Income, GAAP
71
108
136
87
4
-113
-195
-50
-32
-14
53
35
25
- -
Effective Tax Rate (%)
25.49
22.71
24.69
24.16
23.03
- -
- -
- -
- -
- -
9.45
15.46
7.85
- -
Profit Margin (%)
36.35
42.73
34.31
18.71
0.89
-24.9
-60.34
-16.73
-12.57
-5.18
9.33
4.62
3.19
- -
Working Capital
157
586
581
558
406
285
151
142
128
127
193
218
246
246
LT Debt
- -
- -
- -
- -
28
8
13
9
5
31
31
30
28
28
Total Equity
184
633
716
881
715
604
411
362
330
324
378
394
417
417
Return on Invested Capital (%)
43.56
23.04
18.67
10.54
3.18
- -
- -
- -
- -
- -
13.96
8.29
4.83
- -
Return on Capital (%)
46.66
26.41
19.8
10.5
-0.12
- -
- -
- -
- -
- -
14.38
8.9
5.9
- -
Return on Common Equity (%)
46.66
26.58
21.08
11.73
0.55
-17.11
-38.37
-12.83
-9.16
-4.36
14.99
8.95
6.08
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
4
25
79
LT Borrowings
- -
- -
- -
LT Finance Leases
30
31
28
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
946
946
946
Market Capitalization
480
402
324

Working Capital

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
287
333
393
Cash, Cash Equivalents & STI
105
136
182
Accounts Receivable, Net
42
62
53
Inventories
119
112
78
Total Current Liabilities
69
83
147
Payables & Accruals
- -
- -
- -
ST Debt
4
25
79
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-3.91%
3.2%
5.8%
Free Cash Flow
-105.65%
-146%
-1,076.02%
Net Income, GAAP
-353.73%
-124.67%
-28.64%
Sales/Revenue/Turnover
11.3%
27.04%
3.35%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
564
2024
- -
- -
748
2025
- -
- -
773

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.06
2024
- -
- -
0.04
2025
- -
- -
0.03

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Yuan Zhang
Full Time Employees
524
Sector
Health technology
Industry
Pharmaceuticals: other
Address
Building 3 Nanjing JS China
IPO Date
Jan 15, 2014
Website
zs-united.com
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Nanjing Sinolife United Company Limited (3332.HK) is a China-based investment holding company principally engaged in the manufacture and sale of nutritional supplements and health food products. The company offers a range of products including Propolis Capsules, Oyster Plus Capsules, Cranberry Plus EPO Capsules, Bilberry & Lutein Capsules, Red Super Krill soft Capsules, Viralex Attack Capsules, Viralex Revive Drink, Viralex Soothe Throat Lozenges, Vira-Complex Powder, Kids Immune Chews, Kids Vision Chews, Kids Growth Chews, Gummy Candy Series, Zhongsheng Coenzyme capsules, Guishi Weisi capsules, and Green Zhi capsules; it also manufactures and sells cosmetics and skin care products, trades and retails packaged health food products under brands such as Good Health, Zhongsheng, Pannex, and Cobayer, and leases commercial and industrial properties. Nanjing Sinolife United sells its products through distribution networks, e-commerce platforms, cross-border e-commerce channels, chain pharmacies, health goods supermarkets, and tourist souvenir shops, primarily targeting consumers in mainland China, Australia, New Zealand, Vietnam, and other international markets. Founded in 1999 and headquartered at 4/F, Building 3, Qingma 3 Road, Qixia District, Nanjing, Jiangsu Province, China, the company operates around 481 employees and focuses on research, production, and sales in the nutritional supplements industry. In recent developments, the company reported a projected net profit decline for the year ended December 31, 2024, to RMB 32-38 million from RMB 52.6 million in 2023, attributed to substantial investments in brand promotion; it released interim earnings for the half-year ended June 30, 2025, and scheduled a board meeting for March 26, 2025, to review annual results.